Arcus Biosciences Q4 2023 GAAP EPS $(1.08) Misses $(0.98) Estimate, Sales $31.00M Beat $28.37M Estimate
Portfolio Pulse from Benzinga Newsdesk
Arcus Biosciences (NYSE:RCUS) reported Q4 2023 earnings with a GAAP EPS of $(1.08), missing the $(0.98) estimate, and sales of $31.00M, beating the $28.37M estimate. This represents a decrease in both earnings and sales compared to the same period last year.
February 21, 2024 | 9:28 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Arcus Biosciences reported a larger than expected quarterly loss but exceeded sales forecasts in Q4 2023.
The mixed results with a miss on EPS but a beat on sales could lead to uncertain short-term stock price movement. The larger loss compared to estimates and the previous year might concern investors, but the sales beat could offset some negative sentiment.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100